Dr. Reddy's Laboratories Limited
NYSEDr. Reddy's Laboratories reports its Q4 FY2026 results on May 8 with one acute question dominating the setup: can the generic semaglutide opportunity translate into the kind of top-line momentum the stock needs to reverse a month of grinding underperformance? Short interest has eased noticeably in the lead-up to the print, removing one obvious source of pressure. Estimated shorts…
Snapshot as of 7 May 2026
Dr. Reddy's Laboratories reports its Q4 FY2026 results on May 8 with one acute question dominating the setup: can the generic semaglutide opportunity translate into the kind of top-line momentum the stock needs to…
Dr. Reddy's Laboratories received one of its most anticipated regulatory wins in years on Tuesday — Health Canada approved its generic semaglutide injection, making it the first generic version of Novo Nordisk's…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RDY — free to start on ORTEX.
Sign up for free →Open RDY on ORTEX